Sort by:
Need a comprehensive medical report on "Acute Myeloid Leukemia (AML)"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase 3
Terminated
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 447
- Registration Number
- NCT02545283
- Locations
- 🇺🇸
Northwell Health, Great Neck, New York, United States
🇺🇸New York Medical College, Hawthorne, New York, United States
🇺🇸Ichan School of Medicine at Mount Sinai, New York, New York, United States
Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML
Phase 2
Terminated
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2015-08-25
- Last Posted Date
- 2018-06-15
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 13
- Registration Number
- NCT02532010
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors
Not Applicable
Terminated
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Drug: Induction ChemotherapyProcedure: G-PBSC Infusion
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT02519712
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
Phase 1
Completed
- Conditions
- Acute Myeloid Leukemia (AML)Hematologic MalignanciesMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT02492737
An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
Phase 2
Completed
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 326
- Registration Number
- NCT02472145
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Phase 1
Completed
- Conditions
- Acute Myeloid LeukemiaLeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2021-10-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT02464657
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
Phase 2
Completed
- Conditions
- Leukemia
- Interventions
- Biological: Stem Cell InfusionRadiation: Total Body Irradiation (TBI)
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT02441803
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase 2
Terminated
- Conditions
- Therapy-related Acute Myeloid Leukemia and Myelodysplastic SyndromeAcute Myeloid Leukemia, in Relapsede Novo Acute Myeloid Leukemia at Diagnostic
- Interventions
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2019-02-06
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 10
- Registration Number
- NCT02438761
- Locations
- 🇫🇷
Hôpital Saint-Louis, Paris, Ile De France, France
🇫🇷Hôpital Cochin, Paris, Ile De France, France
🇫🇷Institut Curie - Hôpital René Huguenin, Saint-Cloud, Ile De France, France
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
Phase 2
Terminated
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT02433483
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Phase 3
Completed
- Conditions
- Leukemia, Acute Myeloid (AML)
- Interventions
- Drug: LoDAC (Low Dose Cytarabine)Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)Drug: FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 371
- Registration Number
- NCT02421939
- Locations
- 🇺🇸
Site US10011, Birmingham, Alabama, United States
🇺🇸Site US10012, Los Angeles, California, United States
🇺🇸Site US10076, Orange, California, United States